{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreialw47gmrpkvehmf7yh2jasq52gkxizj32uywobku5uzr6hzx3sem",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mmtoy5zvm6l2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreieoqxbpjymzydpvxqq3z7eeot5ewomorbai7lzfxdlhz54tp4xbum"
    },
    "mimeType": "image/jpeg",
    "size": 721183
  },
  "path": "/news/2026-05-kras-degradation-rapid-lung-cancer.html",
  "publishedAt": "2026-05-27T10:01:06.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "KRAS is one of the oncogenes most frequently altered in cancer, mutating in approximately one-third of lung adenocarcinomas. For decades, it was considered undruggable, until the recent approval of the first inhibitors against specific KRAS mutants. However, these treatments often lose efficacy over time due to the emergence of resistance. Now, a new study explores a different pharmacological strategy based on inducing tumor cells to degrade mutant KRAS themselves.",
  "title": "KRAS degradation induces rapid lung cancer regression in preclinical mouse models"
}